Background. All-trans retinoic acid (ATRA) is effective in the treatment of relapsed or refractory acute promyelocytic leukemia (APL), but relapse is the rule if response is unmaintained. Methods. Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/mz/day for 3 months or until
Low plasma level of all-trans retinoic acid after feeding tube administration for acute promyelocytic leukemia
β Scribed by Kimitaka Takitani; Yoshitaka Nakao; Yoshiyuki Kosaka; Akiko Inoue; Chihiro Kawakami; Tomoko Kuno; Hiroshi Tamai
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 185 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The use of arsenic trioxide (As~2~O~3~, ATO) combined with allβtrans retinoic acid (ATRA) has recently been reported to induce remission in patients with acute promyelocytic leukemia (APL). However, its efficiency remains inconclusive mainly due to the small number of the available case
A 22-year-old female presented with acute promyelocytic leukemia (APL). Treatment with all-trans retinoic acid (ATRA) resulted in a severe exacerbation of the coagulopathy 5 days after its introduction. This was complicated by bone marrow necrosis, parenchymal liver damage and acute tubular necrosis